Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

2015; Oxford University Press; Volume: 107; Issue: 2 Linguagem: Inglês

10.1093/jnci/dju413

ISSN

1460-2105

Autores

David Goldstein, Robert H. El-Maraghi, Pascal Hammel, Volker Heinemann, Volker Kunzmann, Javier Sastre, Werner Scheithauer, Salvatore Siena, Josep Tabernero, Luís Teixeira, Giampaolo Tortora, Jean‐Luc Van Laethem, Rosemary Young, Darryl Penenberg, Brian Lu, Alfredo Romano, Daniel D. Von Hoff,

Tópico(s)

Cancer Genomics and Diagnostics

Resumo

Background:Positive findings from the phase III MPACT trial led to the regulatory approval of nab-paclitaxel plus gemcitabine as a treatment option for patients with metastatic pancreatic cancer. This report is an update of overall survival (OS) based on longer follow-up.

Referência(s)